NCT00558961 2023-03-27
GL-CLB-001
Jewish General Hospital
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT01126814 2015-06-24
A Study of Imatinib With Reinduction Chemotherapy Using Mitoxantrone, Etoposide and Cytarabine in Patients With Relapsed/Refractory C-kit Positive (AML) Acute Myeloid Leukemia
University Health Network, Toronto
Phase 1/2 Completed
NCT00028847 2013-09-17
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00015860 2013-06-24
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00081133 2013-06-05
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00093639 2013-05-01
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
Novartis
Phase 1/2 Completed
NCT00053248 2012-05-28
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00244829 2011-11-30
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
Fred Hutchinson Cancer Center
Phase 1/2 Completed